Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Crinetics Pharmaceuticals (NASDAQ: CRNX) announced that Scott Struthers, Ph.D., Founder and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 9:45 a.m. Pacific Time.
The announcement notes an audio-only live webcast will be available and an archived webcast will be posted on the company’s Events & Presentations page at www.crinetics.com/events. Investors seeking 1×1 meetings should contact their conference representative.
Positive
- None.
Negative
- None.
News Market Reaction – CRNX
In the Dec 19 session, CRNX gained 6.36%, reflecting a notable positive market reaction. Argus tracked a trough of -5.6% from its starting point during tracking. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Phase 3 trial start | Positive | +2.4% | First patient dosed in CALM-CAH Phase 3 atumelnant trial for CAH. |
| Dec 10 | Inducement equity grants | Neutral | +2.6% | Inducement stock options and RSUs granted to nine new employees. |
| Dec 03 | Phase 1/2 trial start | Positive | +4.4% | First patient dosed in BRAVESST2 Phase 1/2 trial of CRN09682. |
| Nov 20 | Phase 3 trial start | Positive | +2.1% | First patient randomized in Phase 3 CAREFNDR trial of paltusotine. |
| Nov 10 | Inducement equity grants | Neutral | +3.6% | Inducement options and RSUs granted to new non-executive employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company and clinical milestones have generally been followed by positive 1-day price reactions.
Over the last six weeks, Crinetics reported multiple clinical milestones and corporate updates, including Phase 3 and Phase 1/2 trial initiations and recurring inducement grants. Notably, the first patient dosing in the CALM-CAH Phase 3 trial and the BRAVESST2 Phase 1/2 trial each saw positive next-day moves. Today’s conference participation fits into a period of steady pipeline execution and ongoing talent expansion through inducement equity awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time.
To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.
If you are interested in arranging a 1×1 meeting with management, please contact your conference representative.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
